Results 261 to 270 of about 4,676,099 (307)
Some of the next articles are maybe not open access.
GSH-Responsive Nanoprodrug to Inhibit Glycolysis and Alleviate Immunosuppression for Cancer Therapy.
Nano letters (Print), 2021Blocking energy metabolism of cancer cells and simultaneously stimulating the immune system to perform immune attack are significant for cancer treatment. However, how to potently deliver different drugs with these functions remains a challenge.
Xiaohan Liu +8 more
semanticscholar +1 more source
A Comprehensive and Contemporary Review on Immunosuppression Therapy for Heart Transplantation.
Current pharmaceutical design, 2020Heart transplantation is the standard of therapy for patients with end-stage heart disease. Since the first human-to-human heart transplantation, performed in 1967, advances in organ donation, surgical techniques, organ preservation, perioperative care ...
L. Goldraich +11 more
semanticscholar +1 more source
Immunosuppressive therapy of asthma [PDF]
Journal of Allergy and Clinical Immunology, 1971 Eleven asthmatic men were treated with the antimetabolites thioguanosine or 6-mercaptopurine. Eight completed 12 weeks of treatment. Reversible drug toxicity occurred in 2 patients. Four patients with severe chronic asthma, chronic bronchitis, and continuous wheezing were not improved. Five patients with intermittent asthma of recent onset improved and
Tryggvi Asmundsson +3 more
openaire +2 more sources
Immunosuppressive drug therapy
Current Opinion in Rheumatology, 1989Interstitial lung disease frequently complicates rheumatic disorders, especially polymyositis-dermatomyositis, rheumatoid arthritis, systemic sclerosis, and mixed connective tissue disease. In this article, we review the current data supporting the use of azathioprine, cyclophosphamide, chlorambucil, cyclosporine, and methotrexate in the management of ...
W J, McCune, D K, Vallance, J P, Lynch
openaire +5 more sources
Surgical Clinics of North America, 1999
Although several new immunosuppressive medications have been developed in the past decade, many possible avenues are yet to be explored. Although the newer agents have not reflected any clear benefit in patient or graft survival over CsA or tacrolimus, they have been useful in reducing the incidence and severity of rejection, reducing the concomitant ...
John J. Fung +5 more
openaire +3 more sources
Although several new immunosuppressive medications have been developed in the past decade, many possible avenues are yet to be explored. Although the newer agents have not reflected any clear benefit in patient or graft survival over CsA or tacrolimus, they have been useful in reducing the incidence and severity of rejection, reducing the concomitant ...
John J. Fung +5 more
openaire +3 more sources
Immunosuppressive Therapy in Transplantation [PDF]
Nursing Clinics of North America, 2016 This article discusses immunosuppressive medications used in organ and hematopoietic stem cell transplantation. Induction, maintenance, and rescue therapy are administered throughout different periods during and after transplantation to modulate the immune system response in the recipient to prevent or treat rejection or graft-versus-host disease ...
openaire +2 more sources
Immunosuppressive therapy and the skeleton
Trends in Endocrinology & Metabolism, 1994Glucocorticoids and other immunosuppressive drugs, such as cytoclosporine A, are increasingly used today. One of the most common clinical situations in which they are prescribed is for immunosuppression after organ transplantation. These drugs have diverse effects on the skeleton, however, and one of the most common sequelae of organ transplantation is
S. Epstein, Elizabeth Shane
openaire +3 more sources
Current Opinion in Immunology, 1992
Although Cyclosporin A has improved transplant outcome, its use has serious limitations due to its narrow therapeutic window. New approaches to broaden this window exploit alternative drug formulations, pharmacokinetic profiling and new immunosuppressive agents, such as Rapamycin and Brequinar, which act in a synergistic fashion.
openaire +2 more sources
Although Cyclosporin A has improved transplant outcome, its use has serious limitations due to its narrow therapeutic window. New approaches to broaden this window exploit alternative drug formulations, pharmacokinetic profiling and new immunosuppressive agents, such as Rapamycin and Brequinar, which act in a synergistic fashion.
openaire +2 more sources
Update on immunosuppressive therapy
Current Opinion in Rheumatology, 1998In this review we summarize selected articles that have been published about immunosuppressive agents in the past year. These studies fall into three major categories: 1) use of pulse cyclophosphamide in autoimmune diseases other than systemic lupus erythematosus; 2) use of newer immunosuppressive agents such as cyclosporine and FK506 in a variety of ...
W J McCune, N G Singer
openaire +2 more sources
Advances in Immunosuppressive Therapy
Seminars in Respiratory and Critical Care Medicine, 2007Despite the intense interest in biological agents, traditional immunosuppressive drugs remain the mainstays of treatment for systemic rheumatic diseases that involve the lung. Herewith, we review the mechanism of action, administration and clinical use of immunosuppressive drugs, including cyclophosphamide, chlorambucil, azathioprine, methotrexate ...
Wendy Marder, W. Joseph McCune
openaire +3 more sources